His scientific interests lie mostly in Internal medicine, Oncology, Renal cell carcinoma, Carcinoma and Surgery. His Internal medicine research focuses on Pathology and how it connects with PD-L1. He combines subjects such as Survival rate, Clinical trial, Randomized controlled trial and Hazard ratio with his study of Oncology.
His study looks at the relationship between Renal cell carcinoma and fields such as Clinical endpoint, as well as how they intersect with chemical problems. His Carcinoma research is multidisciplinary, incorporating perspectives in Phases of clinical research, Retrospective cohort study, Combined Modality Therapy, Tyrosine-kinase inhibitor and Biomarker. His Surgery research focuses on subjects like Urology, which are linked to Nivolumab.
Toni K. Choueiri mostly deals with Internal medicine, Oncology, Renal cell carcinoma, Cancer and Sunitinib. His Internal medicine study frequently draws connections to other fields, such as Surgery. Toni K. Choueiri studied Surgery and Urology that intersect with Nephrectomy.
His Oncology research incorporates themes from Nivolumab, Randomized controlled trial, Proportional hazards model and Chemotherapy. His research integrates issues of Targeted therapy, Carcinoma and Cancer research in his study of Renal cell carcinoma. The concepts of his Sunitinib study are interwoven with issues in Bevacizumab, Temsirolimus and Kidney cancer.
His primary scientific interests are in Renal cell carcinoma, Internal medicine, Oncology, Cancer research and Cancer. His Renal cell carcinoma study deals with Hazard ratio intersecting with Urology. While working on this project, he studies both Internal medicine and In patient.
His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Immunotherapy, Targeted therapy and First line. His Cancer research research includes elements of Immune checkpoint, Phenotype, Clear cell renal cell carcinoma, DNA and Carcinoma. His Cancer research integrates issues from Cohort study and MEDLINE.
Toni K. Choueiri mainly investigates Internal medicine, Renal cell carcinoma, Oncology, Cancer and Sunitinib. In his articles, Toni K. Choueiri combines various disciplines, including Internal medicine and In patient. His Renal cell carcinoma study incorporates themes from Cancer research, Adverse effect, Hazard ratio, Confidence interval and Carcinoma.
His Carcinoma research includes themes of Metastatic Urothelial Carcinoma, PD-L1 and Hypoxia. His work carried out in the field of Oncology brings together such families of science as Biomarker and Blockade. His biological study spans a wide range of topics, including Observational study, Cohort study and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George.
The New England Journal of Medicine (2015)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera.
The New England Journal of Medicine (2018)
The Immune Landscape of Cancer
Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet.
The New England Journal of Medicine (2017)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves.
The New England Journal of Medicine (2013)
Post-acute COVID-19 syndrome.
Ani Nalbandian;Kartik Sehgal;Kartik Sehgal;Aakriti Gupta;Aakriti Gupta;Mahesh V Madhavan.
Nature Medicine (2021)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini.
The New England Journal of Medicine (2019)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren.
Journal of Clinical Oncology (2009)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: